THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA TREATMENT: A SYSTEMATIC REVIEW

被引：0
|
作者：
Li, H. [1 ]
Ren, J. [1 ]
Yu, X. [2 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A670 / A670
页数：1
相关论文
共 50 条
  • [41] Long-acting risperidone - A review of its use in schizophrenia
    Harrison, TS
    Goa, KL
    CNS DRUGS, 2004, 18 (02) : 113 - 132
  • [42] Long-Acting Risperidone: A Review of Its Use in Schizophrenia
    Harrison T.S.
    Goa K.L.
    CNS Drugs, 2004, 18 (2) : 113 - 132
  • [43] Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
    Quintero, Javier
    Oyaguez, Itziar
    Gonzalez, Beatriz
    Cuervo-Arango, Ignacio
    Garcia, Ignacio
    Angel Casado, Miguel
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 479 - 490
  • [44] The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: A systematic review of economic evaluations
    Achilla E.
    McCrone P.
    Applied Health Economics and Health Policy, 2013, 11 (2) : 95 - 106
  • [45] Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
    Simon Frey
    Roland Linder
    Georg Juckel
    Tom Stargardt
    The European Journal of Health Economics, 2014, 15 : 133 - 142
  • [46] Cost-effectiveness analysis of long-acting risperidone (LA-RIS) vs haloperidol decanoate and oral olanzapine in the treatment of schizophrenia in Italy
    D'Ausilio, A
    Amaddeo, F
    Mencacci, C
    Munizza, C
    Miadi-Fargier, H
    Berto, P
    VALUE IN HEALTH, 2003, 6 (06) : 694 - 694
  • [47] Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
    Frey, Simon
    Linder, Roland
    Juckel, Georg
    Stargardt, Tom
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (02): : 133 - 142
  • [48] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Kim, H.
    Hong, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S456
  • [49] Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
    Ciwoniuk, M.
    Godlewska, B. R.
    Olajossy-Hilkesberger, L.
    Olajossy, M.
    Marmurowska-Michalowska, H.
    Limon, J.
    Landowski, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S456 - S457
  • [50] Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone
    Olfson, Mark
    Marcus, Steven C.
    Ascher-Svanum, Haya
    SCHIZOPHRENIA BULLETIN, 2007, 33 (06) : 1379 - 1387
12345